A study on the effect of mifepristone on uterine fibroids


  • Ojaswini Yadav Department of Obstetrics and Gynecology, Manipal Hospitals Bangalore, Karnataka, India
  • Amrita Rao Department of Obstetrics and Gynecology, Manipal Hospitals Bangalore, Karnataka, India
  • Madhura Gadekar Department of Obstetrics and Gynecology, Modern Clinic, Wai, Maharashtra, India




Dysmenorrhea, Fibroids, Leiomyoma, Menorrhagia, Mifepristone, PBAC, VAS


Background: Uterine fibroids are the most common pelvic tumors and most common benign tumors in women. Abnormal uterine bleeding and pain are common symptoms of fibroids. The objective of study was to study the effect of mifepristone on uterine fibroids on the basis of change in menstrual pattern, hemoglobin level, fibroid volume and alleviation of pain.

Methods: This prospective study had sample size of 40 subjects with uterine leiomyomas who were recruited from OPD after taking an informed written consent. Follow up of each subject was done after 3 months to see changes in various parameters after giving 3 months of mifepristone 25 mg once daily. Study tools included case reporting form, ultrasonography, blood investigations, pictorial blood loss assessment chart (PBAC) to compare change in menstrual pattern and visual analogue pain scale for comparing alleviation in pain.

Results: In this study, the majority of patients belonged to 41-45 years of age and were para 1 with dominant symptom of menorrhagia. At the end of 3 months the mean baseline fibroid volume decreased by 37.5%, mean hemoglobin improved from 9.37 to 11.05 gm/dl, mean PBAC score reduced from 90.6 to 8.9, 25% of patients had no pain and pain score in 32.5% patients was 1 and in 32.5% patients pain score was 2.

Conclusions: Three months treatment with 25 mg mifepristone daily, effectively controls bleeding, reduces fibroid volume ameliorates pain and abnormal bleeding, improves hemoglobin. It can be recommended as the optimum clinical treatment of fibroids in this dose.



Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and lwhite women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-7.

Berek JS. Berek and Novac’s Gynecology. 16th edn. New Delhi: Wolters Kluwer (India) Pvt Ltd; 2020.

World Health Organization. World Health Organization model list of essential medicines: 22nd list. Geneva: World Health Organization; 2021.

Seth S, Goel N, Singh E, Mathur AS, Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Mid-Life Health. 2013;4:22-6.

Higham JM, O’brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. BJOG. 1990;97(8):734-9.

An efficient machine-learning model based on data augmentation for pain intensity recognition- Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Visual-Analogue-Scale_fig1_340157582. Accessed on 5 March 2023.

Kettel LM, Murphy AA, Morales AJ, Yen SSC. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod. 1994;9(suppl 1):116-20.

Eisinger S. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243-50.

Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril. 1995;64(1):187-90.

Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynecol. 2009;49(1):77-83.

Mukherjee S, Chakraborty S. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri. Niger Med J. 2011;52(3):150-2.

Alakananda D, Basumatary DB, Reddy D. Mifepristone in the medical management of uterine fibroids. Indian J Appl Res. 2019;9(1).

Sruhya M, Hari A. A prospective and interventional study of the role of low dose mifepristone in the management of uterine leiomyoma in perimenopausal women. Saudi J Med Phar Sci. 2017;3:1088-96.

Rani BS, Kumari PD, Usha P. Effect of low dose mifepristone in symptomatic uterine fibroids. J Evid Based Med Healthcare. 2016;3:909-13.

Kapur A, Angomchanu R, Dey M. Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids. J Obstet Gynecol India. 2016;66(S1):494-8.

Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, et al. Low dose mifepristone in medical management of uterine leiomyoma- an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137(6):1154-62.

Shaikh N, Mehra R, Goel P, Kaur R. Mifepristone in fibroids: Comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule. J Midlife Health. 2021;12(1):39-45.

Arora D, Chawla J, Kochar SPS, Sharma JC. A randomized control trial to assess efficacy of Mifepristone in medical management of uterine fibroid. Med J Armed Forces India. 2017;73(3):267-73.

Seher U, Chauhan N, Mangla M. Study the effect of mifepristone on fibroid and uterine volume. Int J Reprod Contracept Obstet Gynecol. 2018;7(12):5016.






Original Research Articles